FDA Determines Regulatory Review Period for TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System

Summary

The Food and Drug Administration has officially confirmed the review period for the TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System, a medical device, in accordance with federal regulations, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.